News

What’s new with DiaSorin Molecular.

Available here is a selection of our latest press releases and news stories.
Filter by year
Published on 12 Nov 2019

DiaSorin Molecular Introduces Primer Pair for Candida auris

Cypress, Calif. (November 12, 2019) – DiaSorin Molecular LLC announced today that it has released a new primer pair for use in laboratory-developed molecular tests that targets the yeast Candida auris. The company is a leader in the development and manufacture of primer pairs with a menu of more than 65 products for bacterial, viral and fungal targets, as well as human genetic mutations. The primer pairs are classified as Analyte Specific Reagents (ASRs), which can be used by high-complexity laboratories to develop their own laboratory developed tests (LDTs).


DiaSorin Molecular
Published on 25 Sep 2019

DiaSorin Molecular’s Simplexa™ VZV Swab Direct Molecular Assay Gets CE Mark

Cypress, Calif. (September 25, 2019) – DiaSorin Molecular LLC announced today that it has received CE marking for its Simplexa™ VZV Swab Direct assay. The new molecular diagnostic test enables the direct detection of varicella-zoster virus (VZV) DNA from both cutaneous and mucocutaneous swab specimens. The assay is used with the LIAISON MDX® instrument and complements the company’s Simplexa HSV 1 & 2 Direct kit. DiaSorin Molecular has also submitted the Simplexa VZV Swab assay to the FDA for 510(k) clearance


DiaSorin Molecular
Published on 30 May 2019

DiaSorin Molecular Receives FDA Clearance for Simplexa™ VZV Direct Molecular Assay

Cypress, Calif. (May 30, 2019) – DiaSorin Molecular LLC announced today that it has received FDA clearance for its new Simplexa VZV Direct assay for use with cerebrospinal fluid (CSF) samples. The new molecular diagnostic test enables the detection of varicella-zoster virus (VZV) DNA from CSF and serves as an effective tool to aid in the diagnosis of meningitis and encephalitis. Requiring only 50µL of patient CSF per test, the assay was developed for use on DiaSorin Molecular’s LIAISON® MDX instrument and complements DiaSorin Molecular’s Simplexa HSV 1 & 2 Direct assay.


DiaSorin Molecular
Published on 16 May 2019

DiaSorin Molecular Attains CE Mark for Simplexa™ HSV 1/2 & VZV Universal Direct Molecular Assay

Cypress, Calif. (May 16, 2019) – DiaSorin Molecular LLC announced today that it has received CE marking for its new SimplexaTM HSV 1/2 & VZV Universal Direct assay. The new molecular diagnostic test enables the direct detection and differentiation of herpes simplex virus (HSV)-1, HSV-2 and varicella-zoster virus (VZV) DNA from cutaneous and mucocutaneous swab specimens. The assay was designed for use on the LIAISON® MDX instrument and generates comprehensive and actionable insight for patients with lesions. 


DiaSorin Molecular
Published on 8 Jan 2019

DiaSorin Molecular Receives FDA Clearance for Bordetella Test

Cypress, Calif., January 8, 2019 – DiaSorin Molecular LLC announced today that it has received FDA clearance for its new Simplexa® Bordetella Direct test. This CLIA moderate-complexity assay is designed for use on the LIAISON® MDX to quickly provide qualitative detection and differentiation of both Bordetella pertussis and Bordetella parapertussis in nasopharyngeal swabs (NPS). The assay is performed directly from NPS samples without extraction and provides results in about an hour.


DiaSorin Molecular
Published on 20 Dec 2018

DiaSorin Molecular Introduces Three New Primer Pairs for Atypical Pneumonia

Cypress, Calif. (December 20, 2018) – DiaSorin Molecular LLC announces the availability of three new primer pairs, or Analyte Specific Reagents (ASRs), which can be used in laboratory-developed tests (LDTs). The specific targets are Legionella species, Chlamydophila pneumoniae and Mycoplasma pneumoniae, all of which may infect the lungs.


DiaSorin Molecular
Published on 26 Nov 2018

DiaSorin Molecular Secures FDA Clearance for Group B Strep Assay

Cypress, Calif. (November 26, 2018) – DiaSorin Molecular LLC announced today that the FDA has cleared its new SimplexaTM GBS Direct assay for diagnostic use. Designed for use on the LIAISON® MDX instrument, the highly sensitive assay enables qualitative detection of Group B Streptococcus (GBS) nucleic acid from 18- to 24-hour Lim broth enrichments of vaginal/rectal specimen swabs obtained from antepartum women. Assay results can be used as an aid in determining the colonization status of antepartum women. The new assay can replace traditional culture testing methods and features an efficient, fast workflow. This is the ninth assay for infectious disease on DiaSorin Molecular’s PCR platform to obtain FDA 510(k) clearance.


DiaSorin Molecular
Published on 18 Oct 2018

DiaSorin Molecular Attains CE Mark for SimplexaTM Group B Strep Direct Molecular Assay

Cypress, Calif. (October 18, 2018) – DiaSorin Molecular LLC announced today that it has attained CE marking for its new SimplexaTM Group B Strep Direct assay. Designed for use on the LIAISON® MDX instrument, the highly sensitive assay enables the direct in vitro detection of Group B Streptococcus (GBS DNA). GBS infection is a significant challenge in the health management of women and newborns. The new assay is more specific than traditional testing methods and features an efficient, fast workflow. This assay has also been submitted to the FDA under their Premarket Notification process, to obtain 510(k) clearance.


DiaSorin Molecular
Published on 2 Oct 2018

DiaSorin Molecular Attains CE Mark for Simplexa™ VZV Direct Molecular Assay

Cypress, Calif. (October 2, 2018) – DiaSorin Molecular LLC announced today that it has received CE marking for its new SimplexaTM VZV Direct assay. The new molecular diagnostic test enables the direct detection of varicella-zoster virus (VZV) DNA from cerebrospinal fluid (CSF). The assay was designed for use on the LIAISON® MDX instrument and will be able to run alongside DiaSorin Molecular’s Simplexa HSV 1 & 2 Direct assay, generating comprehensive and actionable insight for patients with suspected infections of the central nervous system (CNS).


DiaSorin Molecular
Published on 21 Jun 2018

DiaSorin Molecular LLC’s Simplexa® HSV 1 & 2 Direct Assay Receives FDA Clearance for Extended Swab Sample Claims

DiaSorin Molecular LLC announced today that the company has received FDA clearance extending the sample type claims of its Simplexa® HSV 1 & 2 Direct assay. The clearance expands the type of samples that can be tested, from genital swabs to all cutaneous and mucocutaneous swab samples. FDA clearance of the assay for testing cerebrospinal fluid (CSF) samples was received in 2014. With these additional sample types, the DiaSorin Molecular Simplexa HSV 1 & 2 assay now has the most comprehensive sample type coverage for HSV testing in the market. CE Marking for these extended sample claims was attained late last year.


DiaSorin Molecular